Ligand Pharmaceuticals LGND Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other income (expense)?
- Ligand Pharmaceuticals (LGND) reported other income (expense) of -$41.63M in Q1 2026.
- How has Ligand Pharmaceuticals's other income (expense) changed year-over-year?
- Ligand Pharmaceuticals's other income (expense) decreased by 198.1% year-over-year, from -$13.96M to -$41.63M.
- What is the long-term trend for Ligand Pharmaceuticals's other income (expense)?
- Over 3 years (2021 to 2025), Ligand Pharmaceuticals's other income (expense) has grown at a 55.1% compound annual growth rate (CAGR), from -$31.65M to $117.96M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.